MedTrace Logo

HEM1036 Phase 2 Study in Low Anterior Resection Syndrome

NCT05527301 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 67

Last updated 2023-05-25

No results posted yet for this study

Summary

Double-blind, randomized, placebo controlled phase 2 study to explore the efficacy and safety of HEM1036 in the treatment of subjects with LARS

Conditions

  • LARS - Low Anterior Resection Syndrome

Interventions

DRUG

Lactobacillus Fermentum

Lactobacillus Fermentum

DRUG

Placebo

Placebo

Sponsors & Collaborators

  • Premier Research Group plc

    collaborator UNKNOWN

  • HEM Pharma Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-01-01
Primary Completion
2026-01-01
Completion
2026-01-01

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05527301 on ClinicalTrials.gov